Hunan Cancer Hospital
Clinical Trials
51
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)ā¢ Click on a phase to view related trials
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
- Conditions
- Stage IV (Metastatic) Breast Cancer
- Interventions
- Drug: Sacituzumab Govitecan + FulvestrantDrug: Sacituzumab Govitecan + Anastrozole / Exemestane
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT07163481
- Locations
- šØš³
Hunan Cancer Hospital, Changsha, Hunan, China
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
- Conditions
- Gastric Cancer, Adenocarcinoma
- Interventions
- Drug: Shenqi Fuwei MixtureDrug: Shenqi Fuwei Mixture Placebo
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 286
- Registration Number
- NCT07098026
- Locations
- šØš³
Hunan Cancer Hospital, Changsha, Hunan, China
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT07083687
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Conditions
- Metastatic Breast CancerDrug ResistanceHormone Receptor-Positive Breast CancerTriple-Negative Breast Cancer (TNBC)HER2-positive Breast CancerTreatment Decisions
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT07073755
- Locations
- šØš³
Hunan Cancer Hospital, Changsha, Hunan, China
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
- Conditions
- Non Small Cell Lung CancerSmall Cell Lung Cancer
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 121
- Registration Number
- NCT06840704
- Locations
- šØš³
Hunan Cancer Hospital, Changsha, Hunan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
SHR-A1921 Shows Promise in Platinum-Resistant Ovarian Cancer
ā¢ SHR-A1921, an antibody-drug conjugate, demonstrated a 42.3% overall response rate in platinum-resistant ovarian cancer patients at a 3.0 mg/kg dose. ā¢ The disease control rate reached 100% in patients treated with SHR-A1921 at 3.0 mg/kg, with a median duration of response of 9.9 months. ā¢ Manageable safety profiles were observed across both 3.0 mg/kg and 2.0 mg/kg dosing regimens of SHR-A1921 in heavily pretreated patients. ā¢ A phase 3 trial is underway to compare SHR-A1921 with chemotherapy in platinum-resistant epithelial ovarian cancer.